Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
Public ClinicalTrials.gov record NCT05550337. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, THREE-ARM, PLACEBO CONTROLLED, PARALLEL-DESIGN GROUP STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE COMPARING TRIFAROTENE CREAM, 0.005% (TEVA PHARMACEUTICALS, INC. TO AKLIEF ® (TRIFAROTENE 0.005% CREAM) (GALDERMA LABORATORIES, L.P., USA), IN THE TREATMENT OF ACNE VULGARIS
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
Study identification
- NCT ID
- NCT05550337
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 807 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 19, 2022 (Actual)
- Primary completion
- May 9, 2023 (Actual)
- Completion
- May 9, 2023 (Actual)
- Last update posted
- Sep 26, 2024
2022 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 6
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 10011 | West Covina | California | 91790 | — |
| Site 10001 | Brandon | Florida | 33511 | — |
| Site 10003 | Fort Lauderdale | Florida | 33308 | — |
| Site 10004 | Miami | Florida | 33175 | — |
| Site 10005 | Miramar | Florida | 33027 | — |
| Site 10002 | Tampa | Florida | 33609 | — |
| Site 10012 | Baton Rouge | Louisiana | 70809 | — |
| Site 10013 | Baton Rouge | Louisiana | 70809 | — |
| Site 10011 | New Orleans | Louisiana | 70115 | — |
| Site 10008 | Las Cruces | New Mexico | 88011 | — |
| Site 10010 | Saint Clair | Pennsylvania | 15241 | — |
| Site 10009 | Dallas | Texas | 75234 | — |
| Site 10006 | El Paso | Texas | 79902 | — |
| Site 10007 | El Paso | Texas | 79925 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05550337, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 26, 2024 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05550337 live on ClinicalTrials.gov.